| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
1-Formyl-beta-carboline targets multiple cellular pathways. It is a fluorescence probe (ex/em = 390/490 nm) and an antioxidant. It enhances the anti-tumor activity of doxorubicin in vitro and exhibits synergistic effects with hypoxia-activated prodrugs (HAPs). It may act by modulating oxidative stress and apoptosis pathways. The compound has a molecular formula of C12H8N2O and a molecular weight of 196.21 g/mol.
|
|---|---|
| ln Vitro |
1-Formyl-beta-carboline is a fluorescence probe (ex/em = 390/490 nm) and an antioxidant. It enhances the anti-tumor activity of doxorubicin in vitro, showing synergistic effects. It also exhibits synergistic cytotoxic effects when combined with hypoxia-activated prodrugs (HAPs). While specific IC50 values are not provided, it does not have intrinsic anti-tumor activity on its own but enhances the activity of other chemotherapeutics.
|
| ln Vivo |
Specific in vivo activity data for 1-Formyl-beta-carboline is not provided. As an antioxidant and fluorescence probe, it can be used in biological imaging. Its ability to enhance the anti-tumor activity of doxorubicin suggests that it may be effective in combination therapy in vivo, but no specific animal studies are reported. It is for research use only.
|
| Enzyme Assay |
1-Formyl-beta-carboline can be used as a fluorescence probe for imaging applications. Procedure: The compound is dissolved in DMSO and diluted in PBS to 1-10 uM. The fluorescence spectrum is measured (excitation 390 nm, emission 490 nm). For cell-free antioxidant assays, the DPPH radical scavenging activity is measured: the compound (1-100 uM) is mixed with DPPH solution, and absorbance at 517 nm is measured after 30 minutes. The IC50 for radical scavenging is calculated.
|
| Cell Assay |
Cellular synergistic activity with doxorubicin can be assessed in cancer cells. Procedure: Cancer cells (e.g., MCF-7, HeLa, A549) are seeded in 96-well plates (5x103 cells/well). Cells are treated with doxorubicin (0.1-1000 nM) alone or in combination with 1-Formyl-beta-carboline (1-10 uM) for 48-72 hours. Cell viability is measured by MTT or CellTiter-Glo assay. Combination index (CI) values are calculated using the Chou-Talalay method. A CI < 1 indicates synergy. Under hypoxic conditions (1% O2), cells are co-treated with hypoxia-activated prodrugs (e.g., tirapazamine).
|
| Animal Protocol |
The in vivo efficacy of 1-Formyl-beta-carboline as a combination agent can be evaluated in a mouse xenograft model of cancer. Procedure: Female athymic nude mice are inoculated subcutaneously with 5x10⁶ cancer cells (e.g., A549 or MCF-7). When tumors reach 150-200 mm3, mice are randomized into groups (n=10). Doxorubicin (5 mg/kg, i.p.) is administered alone or in combination with 1-Formyl-beta-carboline (10-50 mg/kg, i.p.) once daily for 14 days. Tumor volumes are measured every 3 days. A greater reduction in tumor volume in the combination group compared to doxorubicin alone indicates synergy.
|
| ADME/Pharmacokinetics |
Specific PK data for 1-Formyl-beta-carboline is not provided. As a small molecule, it is likely to have moderate lipophilicity and may be absorbed. It is stored as a powder at -20degC. For in vivo use, it can be formulated in 5% DMSO, 40% PEG300, 5% Tween 80, 50% saline.
|
| Toxicity/Toxicokinetics |
Specific toxicology data for 1-Formyl-beta-carboline is not provided. As a beta-carboline alkaloid, it may have neuroactive properties, but no specific toxicities are reported. Standard safety precautions for handling organic compounds should be followed. The compound is for research use only and is not an approved drug.
|
| References | |
| Additional Infomation |
9H-pyrido(3,4-b)indole-1-carbaldehyde is a member of the β-carboline family. 9H-pyrido[3,4-b]indole-1-carbaldehyde has been reported in *Picrasma quassioides*, and relevant data are available for reference.
1-Formyl-beta-carboline is a beta-carboline alkaloid with fluorescence properties (ex/em = 390/490 nm) and antioxidant activity. It enhances the anti-tumor activity of doxorubicin in vitro and exhibits synergistic effects with hypoxia-activated prodrugs. It is used as a research tool in cancer combination therapy studies. It is for research use only and is not an approved drug. |
| Molecular Formula |
C12H8N2O
|
|---|---|
| Molecular Weight |
196.20
|
| Exact Mass |
196.064
|
| CAS # |
20127-63-3
|
| PubChem CID |
5317375
|
| Appearance |
Solid Powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
440.8±25.0 °C at 760 mmHg
|
| Flash Point |
220.8±29.6 °C
|
| Vapour Pressure |
0.0±1.1 mmHg at 25°C
|
| Index of Refraction |
1.818
|
| LogP |
2.51
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
15
|
| Complexity |
256
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC=C2C(=C1)C3=C(C(=NC=C3)C=O)N2
|
| InChi Key |
CHQBGSRZQLMDEX-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C12H8N2O/c15-7-11-12-9(5-6-13-11)8-3-1-2-4-10(8)14-12/h1-7,14H
|
| Chemical Name |
9H-pyrido[3,4-b]indole-1-carbaldehyde
|
| Synonyms |
Quassine C
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.0968 mL | 25.4842 mL | 50.9684 mL | |
| 5 mM | 1.0194 mL | 5.0968 mL | 10.1937 mL | |
| 10 mM | 0.5097 mL | 2.5484 mL | 5.0968 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
